Global Pentazocine Market

Pentazocine Comprehensive Study by Application (Postoperative pain, Chronic Pain, Obstetrics, Renal and biliary colic, Myocardial infarction, Intravenous anaesthesia and premedication, Others), Patient Type (Adults, Children, Elderly), Route of administration (Intramuscular, Intravenous, Subcutaneous, Oral), Dosage regimens (Below 25mg, 50 mg, 60 mg above), Dosage Form (Parenteral forms, Oral forms, Rectal forms) Players and Region - Global Market Outlook to 2026

Pentazocine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pentazocine Market Scope?
Pentazocine is a painkiller used to treat moderate to severe pain, to relieve moderate to severe pain. It may also be used before surgery or with a general anaesthetic (medicine that puts you to sleep). Pentazocine belongs to the group of medicines called narcotic analgesics (pain medicines). It acts on the central nervous system (CNS) to relieve pain. Early It was used as a substitute for morphine. Pentazocine reversed the respiratory depression produced by fentanyl and the patients were conscious and co-operative very soon after the operation

The Pentazocine market study is being classified, by Application (Postoperative pain, Chronic Pain, Obstetrics, Renal and biliary colic, Myocardial infarction, Intravenous anaesthesia and premedication and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Pentazocine market throughout the predicted period.

Merck KGaA (Germany), LUPIN PHARMACEUTICALS (United States), Teva(United States), Pfizer (United States), Sun Pharmaceutical Industries Limited(India), Hospira, Inc.(United States), Keltman Pharmaceuticals Inc.(United States), Golden State Medical Supply, Inc. (United States), Actavis Totowa LLC(United States) and Sanofi aventis us llc(Ireland) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Pentazocine market by Type, Application and Region.

On the basis of geography, the market of Pentazocine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Drivers
  • Increased adoption of Pentazocine over morphine

Opportunities
  • The growing use of pain killers as it is a useful function in the management of moderate to severe pain when used intravenously or intramuscularly

Restraints
  • Increasing addiction problem associated with the use of pentazocine

Challenges
  • lack of knowledge approximately the right usage of Pentazocine


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Pentazocine Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Application
  • Postoperative pain
  • Chronic Pain
  • Obstetrics
  • Renal and biliary colic
  • Myocardial infarction
  • Intravenous anaesthesia and premedication
  • Others
By Patient Type
  • Adults
  • Children
  • Elderly

By Route of administration
  • Intramuscular
  • Intravenous
  • Subcutaneous
  • Oral

By Dosage regimens
  • Below 25mg
  • 50 mg
  • 60 mg above

By Dosage Form
  • Parenteral forms
  • Oral forms
  • Rectal forms

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased adoption of Pentazocine over morphine
    • 3.3. Market Challenges
      • 3.3.1. Lack of knowledge approximately the right usage of Pentazocine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pentazocine, by Application, Patient Type, Route of administration , Dosage regimens, Dosage Form and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pentazocine (Value)
      • 5.2.1. Global Pentazocine by: Application (Value)
        • 5.2.1.1. Postoperative pain
        • 5.2.1.2. Chronic Pain
        • 5.2.1.3. Obstetrics
        • 5.2.1.4. Renal and biliary colic
        • 5.2.1.5. Myocardial infarction
        • 5.2.1.6. Intravenous anaesthesia and premedication
        • 5.2.1.7. Others
      • 5.2.2. Global Pentazocine by: Patient Type (Value)
        • 5.2.2.1. Adults
        • 5.2.2.2. Children
        • 5.2.2.3. Elderly
      • 5.2.3. Global Pentazocine by: Dosage regimens (Value)
        • 5.2.3.1. Below 25mg
        • 5.2.3.2. 50 mg
        • 5.2.3.3. 60 mg above
      • 5.2.4. Global Pentazocine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Pentazocine (Volume)
      • 5.3.1. Global Pentazocine by: Application (Volume)
        • 5.3.1.1. Postoperative pain
        • 5.3.1.2. Chronic Pain
        • 5.3.1.3. Obstetrics
        • 5.3.1.4. Renal and biliary colic
        • 5.3.1.5. Myocardial infarction
        • 5.3.1.6. Intravenous anaesthesia and premedication
        • 5.3.1.7. Others
      • 5.3.2. Global Pentazocine by: Patient Type (Volume)
        • 5.3.2.1. Adults
        • 5.3.2.2. Children
        • 5.3.2.3. Elderly
      • 5.3.3. Global Pentazocine by: Dosage regimens (Volume)
        • 5.3.3.1. Below 25mg
        • 5.3.3.2. 50 mg
        • 5.3.3.3. 60 mg above
      • 5.3.4. Global Pentazocine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Pentazocine (Price)
  • 6. Pentazocine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. LUPIN PHARMACEUTICALS (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva(United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sun Pharmaceutical Industries Limited(India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hospira, Inc.(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Keltman Pharmaceuticals Inc.(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Golden State Medical Supply, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Actavis Totowa LLC(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi aventis us llc(Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pentazocine Sale, by Application, Patient Type, Route of administration , Dosage regimens, Dosage Form and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pentazocine (Value)
      • 7.2.1. Global Pentazocine by: Application (Value)
        • 7.2.1.1. Postoperative pain
        • 7.2.1.2. Chronic Pain
        • 7.2.1.3. Obstetrics
        • 7.2.1.4. Renal and biliary colic
        • 7.2.1.5. Myocardial infarction
        • 7.2.1.6. Intravenous anaesthesia and premedication
        • 7.2.1.7. Others
      • 7.2.2. Global Pentazocine by: Patient Type (Value)
        • 7.2.2.1. Adults
        • 7.2.2.2. Children
        • 7.2.2.3. Elderly
      • 7.2.3. Global Pentazocine by: Dosage regimens (Value)
        • 7.2.3.1. Below 25mg
        • 7.2.3.2. 50 mg
        • 7.2.3.3. 60 mg above
      • 7.2.4. Global Pentazocine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Pentazocine (Volume)
      • 7.3.1. Global Pentazocine by: Application (Volume)
        • 7.3.1.1. Postoperative pain
        • 7.3.1.2. Chronic Pain
        • 7.3.1.3. Obstetrics
        • 7.3.1.4. Renal and biliary colic
        • 7.3.1.5. Myocardial infarction
        • 7.3.1.6. Intravenous anaesthesia and premedication
        • 7.3.1.7. Others
      • 7.3.2. Global Pentazocine by: Patient Type (Volume)
        • 7.3.2.1. Adults
        • 7.3.2.2. Children
        • 7.3.2.3. Elderly
      • 7.3.3. Global Pentazocine by: Dosage regimens (Volume)
        • 7.3.3.1. Below 25mg
        • 7.3.3.2. 50 mg
        • 7.3.3.3. 60 mg above
      • 7.3.4. Global Pentazocine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Pentazocine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pentazocine: by Application(USD Million)
  • Table 2. Pentazocine Postoperative pain , by Region USD Million (2015-2020)
  • Table 3. Pentazocine Chronic Pain , by Region USD Million (2015-2020)
  • Table 4. Pentazocine Obstetrics , by Region USD Million (2015-2020)
  • Table 5. Pentazocine Renal and biliary colic , by Region USD Million (2015-2020)
  • Table 6. Pentazocine Myocardial infarction , by Region USD Million (2015-2020)
  • Table 7. Pentazocine Intravenous anaesthesia and premedication , by Region USD Million (2015-2020)
  • Table 8. Pentazocine Others , by Region USD Million (2015-2020)
  • Table 9. Pentazocine: by Patient Type(USD Million)
  • Table 10. Pentazocine Adults , by Region USD Million (2015-2020)
  • Table 11. Pentazocine Children , by Region USD Million (2015-2020)
  • Table 12. Pentazocine Elderly , by Region USD Million (2015-2020)
  • Table 13. Pentazocine: by Dosage regimens(USD Million)
  • Table 14. Pentazocine Below 25mg , by Region USD Million (2015-2020)
  • Table 15. Pentazocine 50 mg , by Region USD Million (2015-2020)
  • Table 16. Pentazocine 60 mg above , by Region USD Million (2015-2020)
  • Table 17. South America Pentazocine, by Country USD Million (2015-2020)
  • Table 18. South America Pentazocine, by Application USD Million (2015-2020)
  • Table 19. South America Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 20. South America Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 21. South America Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 22. South America Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 23. Brazil Pentazocine, by Application USD Million (2015-2020)
  • Table 24. Brazil Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 25. Brazil Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 26. Brazil Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 27. Brazil Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 28. Argentina Pentazocine, by Application USD Million (2015-2020)
  • Table 29. Argentina Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 30. Argentina Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 31. Argentina Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 32. Argentina Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 33. Rest of South America Pentazocine, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 35. Rest of South America Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 36. Rest of South America Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 37. Rest of South America Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 38. Asia Pacific Pentazocine, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Pentazocine, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 41. Asia Pacific Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 42. Asia Pacific Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 43. Asia Pacific Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 44. China Pentazocine, by Application USD Million (2015-2020)
  • Table 45. China Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 46. China Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 47. China Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 48. China Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 49. Japan Pentazocine, by Application USD Million (2015-2020)
  • Table 50. Japan Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 51. Japan Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 52. Japan Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 53. Japan Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 54. India Pentazocine, by Application USD Million (2015-2020)
  • Table 55. India Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 56. India Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 57. India Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 58. India Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 59. South Korea Pentazocine, by Application USD Million (2015-2020)
  • Table 60. South Korea Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 61. South Korea Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 62. South Korea Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 63. South Korea Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 64. Taiwan Pentazocine, by Application USD Million (2015-2020)
  • Table 65. Taiwan Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 66. Taiwan Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 67. Taiwan Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 68. Taiwan Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 69. Australia Pentazocine, by Application USD Million (2015-2020)
  • Table 70. Australia Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 71. Australia Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 72. Australia Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 73. Australia Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Pentazocine, by Application USD Million (2015-2020)
  • Table 75. Rest of Asia-Pacific Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 76. Rest of Asia-Pacific Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 77. Rest of Asia-Pacific Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 79. Europe Pentazocine, by Country USD Million (2015-2020)
  • Table 80. Europe Pentazocine, by Application USD Million (2015-2020)
  • Table 81. Europe Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 82. Europe Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 83. Europe Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 84. Europe Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 85. Germany Pentazocine, by Application USD Million (2015-2020)
  • Table 86. Germany Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 87. Germany Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 88. Germany Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 89. Germany Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 90. France Pentazocine, by Application USD Million (2015-2020)
  • Table 91. France Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 92. France Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 93. France Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 94. France Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 95. Italy Pentazocine, by Application USD Million (2015-2020)
  • Table 96. Italy Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 97. Italy Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 98. Italy Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 99. Italy Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 100. United Kingdom Pentazocine, by Application USD Million (2015-2020)
  • Table 101. United Kingdom Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 102. United Kingdom Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 103. United Kingdom Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 104. United Kingdom Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 105. Netherlands Pentazocine, by Application USD Million (2015-2020)
  • Table 106. Netherlands Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 107. Netherlands Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 108. Netherlands Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 109. Netherlands Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 110. Rest of Europe Pentazocine, by Application USD Million (2015-2020)
  • Table 111. Rest of Europe Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 112. Rest of Europe Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 113. Rest of Europe Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 114. Rest of Europe Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 115. MEA Pentazocine, by Country USD Million (2015-2020)
  • Table 116. MEA Pentazocine, by Application USD Million (2015-2020)
  • Table 117. MEA Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 118. MEA Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 119. MEA Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 120. MEA Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 121. Middle East Pentazocine, by Application USD Million (2015-2020)
  • Table 122. Middle East Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 123. Middle East Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 124. Middle East Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 125. Middle East Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 126. Africa Pentazocine, by Application USD Million (2015-2020)
  • Table 127. Africa Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 128. Africa Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 129. Africa Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 130. Africa Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 131. North America Pentazocine, by Country USD Million (2015-2020)
  • Table 132. North America Pentazocine, by Application USD Million (2015-2020)
  • Table 133. North America Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 134. North America Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 135. North America Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 136. North America Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 137. United States Pentazocine, by Application USD Million (2015-2020)
  • Table 138. United States Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 139. United States Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 140. United States Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 141. United States Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 142. Canada Pentazocine, by Application USD Million (2015-2020)
  • Table 143. Canada Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 144. Canada Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 145. Canada Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 146. Canada Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 147. Mexico Pentazocine, by Application USD Million (2015-2020)
  • Table 148. Mexico Pentazocine, by Patient Type USD Million (2015-2020)
  • Table 149. Mexico Pentazocine, by Route of administration USD Million (2015-2020)
  • Table 150. Mexico Pentazocine, by Dosage regimens USD Million (2015-2020)
  • Table 151. Mexico Pentazocine, by Dosage Form USD Million (2015-2020)
  • Table 152. Pentazocine Sales: by Application(K Tons)
  • Table 153. Pentazocine Sales Postoperative pain , by Region K Tons (2015-2020)
  • Table 154. Pentazocine Sales Chronic Pain , by Region K Tons (2015-2020)
  • Table 155. Pentazocine Sales Obstetrics , by Region K Tons (2015-2020)
  • Table 156. Pentazocine Sales Renal and biliary colic , by Region K Tons (2015-2020)
  • Table 157. Pentazocine Sales Myocardial infarction , by Region K Tons (2015-2020)
  • Table 158. Pentazocine Sales Intravenous anaesthesia and premedication , by Region K Tons (2015-2020)
  • Table 159. Pentazocine Sales Others , by Region K Tons (2015-2020)
  • Table 160. Pentazocine Sales: by Patient Type(K Tons)
  • Table 161. Pentazocine Sales Adults , by Region K Tons (2015-2020)
  • Table 162. Pentazocine Sales Children , by Region K Tons (2015-2020)
  • Table 163. Pentazocine Sales Elderly , by Region K Tons (2015-2020)
  • Table 164. Pentazocine Sales: by Dosage regimens(K Tons)
  • Table 165. Pentazocine Sales Below 25mg , by Region K Tons (2015-2020)
  • Table 166. Pentazocine Sales 50 mg , by Region K Tons (2015-2020)
  • Table 167. Pentazocine Sales 60 mg above , by Region K Tons (2015-2020)
  • Table 168. South America Pentazocine Sales, by Country K Tons (2015-2020)
  • Table 169. South America Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 170. South America Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 171. South America Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 172. South America Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 173. South America Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 174. Brazil Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 175. Brazil Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 176. Brazil Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 177. Brazil Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 178. Brazil Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 179. Argentina Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 180. Argentina Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 181. Argentina Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 182. Argentina Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 183. Argentina Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 184. Rest of South America Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 185. Rest of South America Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 186. Rest of South America Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 187. Rest of South America Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 188. Rest of South America Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 189. Asia Pacific Pentazocine Sales, by Country K Tons (2015-2020)
  • Table 190. Asia Pacific Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 191. Asia Pacific Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 192. Asia Pacific Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 193. Asia Pacific Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 194. Asia Pacific Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 195. China Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 196. China Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 197. China Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 198. China Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 199. China Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 200. Japan Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 201. Japan Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 202. Japan Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 203. Japan Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 204. Japan Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 205. India Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 206. India Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 207. India Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 208. India Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 209. India Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 210. South Korea Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 211. South Korea Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 212. South Korea Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 213. South Korea Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 214. South Korea Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 215. Taiwan Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 216. Taiwan Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 217. Taiwan Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 218. Taiwan Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 219. Taiwan Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 220. Australia Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 221. Australia Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 222. Australia Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 223. Australia Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 224. Australia Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 225. Rest of Asia-Pacific Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 226. Rest of Asia-Pacific Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 227. Rest of Asia-Pacific Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 228. Rest of Asia-Pacific Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 229. Rest of Asia-Pacific Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 230. Europe Pentazocine Sales, by Country K Tons (2015-2020)
  • Table 231. Europe Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 232. Europe Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 233. Europe Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 234. Europe Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 235. Europe Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 236. Germany Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 237. Germany Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 238. Germany Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 239. Germany Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 240. Germany Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 241. France Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 242. France Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 243. France Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 244. France Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 245. France Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 246. Italy Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 247. Italy Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 248. Italy Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 249. Italy Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 250. Italy Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 251. United Kingdom Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 252. United Kingdom Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 253. United Kingdom Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 254. United Kingdom Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 255. United Kingdom Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 256. Netherlands Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 257. Netherlands Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 258. Netherlands Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 259. Netherlands Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 260. Netherlands Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 261. Rest of Europe Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 262. Rest of Europe Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 263. Rest of Europe Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 264. Rest of Europe Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 265. Rest of Europe Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 266. MEA Pentazocine Sales, by Country K Tons (2015-2020)
  • Table 267. MEA Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 268. MEA Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 269. MEA Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 270. MEA Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 271. MEA Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 272. Middle East Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 273. Middle East Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 274. Middle East Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 275. Middle East Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 276. Middle East Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 277. Africa Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 278. Africa Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 279. Africa Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 280. Africa Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 281. Africa Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 282. North America Pentazocine Sales, by Country K Tons (2015-2020)
  • Table 283. North America Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 284. North America Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 285. North America Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 286. North America Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 287. North America Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 288. United States Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 289. United States Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 290. United States Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 291. United States Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 292. United States Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 293. Canada Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 294. Canada Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 295. Canada Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 296. Canada Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 297. Canada Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 298. Mexico Pentazocine Sales, by Application K Tons (2015-2020)
  • Table 299. Mexico Pentazocine Sales, by Patient Type K Tons (2015-2020)
  • Table 300. Mexico Pentazocine Sales, by Route of administration K Tons (2015-2020)
  • Table 301. Mexico Pentazocine Sales, by Dosage regimens K Tons (2015-2020)
  • Table 302. Mexico Pentazocine Sales, by Dosage Form K Tons (2015-2020)
  • Table 303. Company Basic Information, Sales Area and Its Competitors
  • Table 304. Company Basic Information, Sales Area and Its Competitors
  • Table 305. Company Basic Information, Sales Area and Its Competitors
  • Table 306. Company Basic Information, Sales Area and Its Competitors
  • Table 307. Company Basic Information, Sales Area and Its Competitors
  • Table 308. Company Basic Information, Sales Area and Its Competitors
  • Table 309. Company Basic Information, Sales Area and Its Competitors
  • Table 310. Company Basic Information, Sales Area and Its Competitors
  • Table 311. Company Basic Information, Sales Area and Its Competitors
  • Table 312. Company Basic Information, Sales Area and Its Competitors
  • Table 313. Pentazocine: by Application(USD Million)
  • Table 314. Pentazocine Postoperative pain , by Region USD Million (2021-2026)
  • Table 315. Pentazocine Chronic Pain , by Region USD Million (2021-2026)
  • Table 316. Pentazocine Obstetrics , by Region USD Million (2021-2026)
  • Table 317. Pentazocine Renal and biliary colic , by Region USD Million (2021-2026)
  • Table 318. Pentazocine Myocardial infarction , by Region USD Million (2021-2026)
  • Table 319. Pentazocine Intravenous anaesthesia and premedication , by Region USD Million (2021-2026)
  • Table 320. Pentazocine Others , by Region USD Million (2021-2026)
  • Table 321. Pentazocine: by Patient Type(USD Million)
  • Table 322. Pentazocine Adults , by Region USD Million (2021-2026)
  • Table 323. Pentazocine Children , by Region USD Million (2021-2026)
  • Table 324. Pentazocine Elderly , by Region USD Million (2021-2026)
  • Table 325. Pentazocine: by Dosage regimens(USD Million)
  • Table 326. Pentazocine Below 25mg , by Region USD Million (2021-2026)
  • Table 327. Pentazocine 50 mg , by Region USD Million (2021-2026)
  • Table 328. Pentazocine 60 mg above , by Region USD Million (2021-2026)
  • Table 329. South America Pentazocine, by Country USD Million (2021-2026)
  • Table 330. South America Pentazocine, by Application USD Million (2021-2026)
  • Table 331. South America Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 332. South America Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 333. South America Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 334. South America Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 335. Brazil Pentazocine, by Application USD Million (2021-2026)
  • Table 336. Brazil Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 337. Brazil Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 338. Brazil Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 339. Brazil Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 340. Argentina Pentazocine, by Application USD Million (2021-2026)
  • Table 341. Argentina Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 342. Argentina Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 343. Argentina Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 344. Argentina Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 345. Rest of South America Pentazocine, by Application USD Million (2021-2026)
  • Table 346. Rest of South America Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 347. Rest of South America Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 348. Rest of South America Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 349. Rest of South America Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 350. Asia Pacific Pentazocine, by Country USD Million (2021-2026)
  • Table 351. Asia Pacific Pentazocine, by Application USD Million (2021-2026)
  • Table 352. Asia Pacific Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 353. Asia Pacific Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 354. Asia Pacific Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 355. Asia Pacific Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 356. China Pentazocine, by Application USD Million (2021-2026)
  • Table 357. China Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 358. China Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 359. China Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 360. China Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 361. Japan Pentazocine, by Application USD Million (2021-2026)
  • Table 362. Japan Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 363. Japan Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 364. Japan Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 365. Japan Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 366. India Pentazocine, by Application USD Million (2021-2026)
  • Table 367. India Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 368. India Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 369. India Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 370. India Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 371. South Korea Pentazocine, by Application USD Million (2021-2026)
  • Table 372. South Korea Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 373. South Korea Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 374. South Korea Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 375. South Korea Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 376. Taiwan Pentazocine, by Application USD Million (2021-2026)
  • Table 377. Taiwan Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 378. Taiwan Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 379. Taiwan Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 380. Taiwan Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 381. Australia Pentazocine, by Application USD Million (2021-2026)
  • Table 382. Australia Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 383. Australia Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 384. Australia Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 385. Australia Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 386. Rest of Asia-Pacific Pentazocine, by Application USD Million (2021-2026)
  • Table 387. Rest of Asia-Pacific Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 388. Rest of Asia-Pacific Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 389. Rest of Asia-Pacific Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 390. Rest of Asia-Pacific Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 391. Europe Pentazocine, by Country USD Million (2021-2026)
  • Table 392. Europe Pentazocine, by Application USD Million (2021-2026)
  • Table 393. Europe Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 394. Europe Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 395. Europe Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 396. Europe Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 397. Germany Pentazocine, by Application USD Million (2021-2026)
  • Table 398. Germany Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 399. Germany Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 400. Germany Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 401. Germany Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 402. France Pentazocine, by Application USD Million (2021-2026)
  • Table 403. France Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 404. France Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 405. France Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 406. France Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 407. Italy Pentazocine, by Application USD Million (2021-2026)
  • Table 408. Italy Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 409. Italy Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 410. Italy Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 411. Italy Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 412. United Kingdom Pentazocine, by Application USD Million (2021-2026)
  • Table 413. United Kingdom Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 414. United Kingdom Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 415. United Kingdom Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 416. United Kingdom Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 417. Netherlands Pentazocine, by Application USD Million (2021-2026)
  • Table 418. Netherlands Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 419. Netherlands Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 420. Netherlands Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 421. Netherlands Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 422. Rest of Europe Pentazocine, by Application USD Million (2021-2026)
  • Table 423. Rest of Europe Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 424. Rest of Europe Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 425. Rest of Europe Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 426. Rest of Europe Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 427. MEA Pentazocine, by Country USD Million (2021-2026)
  • Table 428. MEA Pentazocine, by Application USD Million (2021-2026)
  • Table 429. MEA Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 430. MEA Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 431. MEA Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 432. MEA Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 433. Middle East Pentazocine, by Application USD Million (2021-2026)
  • Table 434. Middle East Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 435. Middle East Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 436. Middle East Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 437. Middle East Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 438. Africa Pentazocine, by Application USD Million (2021-2026)
  • Table 439. Africa Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 440. Africa Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 441. Africa Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 442. Africa Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 443. North America Pentazocine, by Country USD Million (2021-2026)
  • Table 444. North America Pentazocine, by Application USD Million (2021-2026)
  • Table 445. North America Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 446. North America Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 447. North America Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 448. North America Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 449. United States Pentazocine, by Application USD Million (2021-2026)
  • Table 450. United States Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 451. United States Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 452. United States Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 453. United States Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 454. Canada Pentazocine, by Application USD Million (2021-2026)
  • Table 455. Canada Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 456. Canada Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 457. Canada Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 458. Canada Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 459. Mexico Pentazocine, by Application USD Million (2021-2026)
  • Table 460. Mexico Pentazocine, by Patient Type USD Million (2021-2026)
  • Table 461. Mexico Pentazocine, by Route of administration USD Million (2021-2026)
  • Table 462. Mexico Pentazocine, by Dosage regimens USD Million (2021-2026)
  • Table 463. Mexico Pentazocine, by Dosage Form USD Million (2021-2026)
  • Table 464. Pentazocine Sales: by Application(K Tons)
  • Table 465. Pentazocine Sales Postoperative pain , by Region K Tons (2021-2026)
  • Table 466. Pentazocine Sales Chronic Pain , by Region K Tons (2021-2026)
  • Table 467. Pentazocine Sales Obstetrics , by Region K Tons (2021-2026)
  • Table 468. Pentazocine Sales Renal and biliary colic , by Region K Tons (2021-2026)
  • Table 469. Pentazocine Sales Myocardial infarction , by Region K Tons (2021-2026)
  • Table 470. Pentazocine Sales Intravenous anaesthesia and premedication , by Region K Tons (2021-2026)
  • Table 471. Pentazocine Sales Others , by Region K Tons (2021-2026)
  • Table 472. Pentazocine Sales: by Patient Type(K Tons)
  • Table 473. Pentazocine Sales Adults , by Region K Tons (2021-2026)
  • Table 474. Pentazocine Sales Children , by Region K Tons (2021-2026)
  • Table 475. Pentazocine Sales Elderly , by Region K Tons (2021-2026)
  • Table 476. Pentazocine Sales: by Dosage regimens(K Tons)
  • Table 477. Pentazocine Sales Below 25mg , by Region K Tons (2021-2026)
  • Table 478. Pentazocine Sales 50 mg , by Region K Tons (2021-2026)
  • Table 479. Pentazocine Sales 60 mg above , by Region K Tons (2021-2026)
  • Table 480. South America Pentazocine Sales, by Country K Tons (2021-2026)
  • Table 481. South America Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 482. South America Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 483. South America Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 484. South America Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 485. South America Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 486. Brazil Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 487. Brazil Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 488. Brazil Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 489. Brazil Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 490. Brazil Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 491. Argentina Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 492. Argentina Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 493. Argentina Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 494. Argentina Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 495. Argentina Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 496. Rest of South America Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 497. Rest of South America Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 498. Rest of South America Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 499. Rest of South America Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 500. Rest of South America Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 501. Asia Pacific Pentazocine Sales, by Country K Tons (2021-2026)
  • Table 502. Asia Pacific Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 503. Asia Pacific Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 504. Asia Pacific Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 505. Asia Pacific Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 506. Asia Pacific Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 507. China Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 508. China Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 509. China Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 510. China Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 511. China Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 512. Japan Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 513. Japan Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 514. Japan Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 515. Japan Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 516. Japan Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 517. India Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 518. India Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 519. India Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 520. India Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 521. India Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 522. South Korea Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 523. South Korea Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 524. South Korea Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 525. South Korea Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 526. South Korea Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 527. Taiwan Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 528. Taiwan Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 529. Taiwan Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 530. Taiwan Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 531. Taiwan Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 532. Australia Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 533. Australia Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 534. Australia Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 535. Australia Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 536. Australia Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 537. Rest of Asia-Pacific Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 538. Rest of Asia-Pacific Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 539. Rest of Asia-Pacific Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 540. Rest of Asia-Pacific Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 541. Rest of Asia-Pacific Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 542. Europe Pentazocine Sales, by Country K Tons (2021-2026)
  • Table 543. Europe Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 544. Europe Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 545. Europe Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 546. Europe Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 547. Europe Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 548. Germany Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 549. Germany Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 550. Germany Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 551. Germany Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 552. Germany Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 553. France Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 554. France Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 555. France Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 556. France Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 557. France Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 558. Italy Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 559. Italy Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 560. Italy Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 561. Italy Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 562. Italy Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 563. United Kingdom Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 564. United Kingdom Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 565. United Kingdom Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 566. United Kingdom Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 567. United Kingdom Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 568. Netherlands Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 569. Netherlands Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 570. Netherlands Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 571. Netherlands Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 572. Netherlands Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 573. Rest of Europe Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 574. Rest of Europe Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 575. Rest of Europe Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 576. Rest of Europe Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 577. Rest of Europe Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 578. MEA Pentazocine Sales, by Country K Tons (2021-2026)
  • Table 579. MEA Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 580. MEA Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 581. MEA Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 582. MEA Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 583. MEA Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 584. Middle East Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 585. Middle East Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 586. Middle East Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 587. Middle East Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 588. Middle East Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 589. Africa Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 590. Africa Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 591. Africa Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 592. Africa Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 593. Africa Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 594. North America Pentazocine Sales, by Country K Tons (2021-2026)
  • Table 595. North America Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 596. North America Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 597. North America Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 598. North America Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 599. North America Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 600. United States Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 601. United States Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 602. United States Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 603. United States Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 604. United States Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 605. Canada Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 606. Canada Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 607. Canada Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 608. Canada Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 609. Canada Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 610. Mexico Pentazocine Sales, by Application K Tons (2021-2026)
  • Table 611. Mexico Pentazocine Sales, by Patient Type K Tons (2021-2026)
  • Table 612. Mexico Pentazocine Sales, by Route of administration K Tons (2021-2026)
  • Table 613. Mexico Pentazocine Sales, by Dosage regimens K Tons (2021-2026)
  • Table 614. Mexico Pentazocine Sales, by Dosage Form K Tons (2021-2026)
  • Table 615. Research Programs/Design for This Report
  • Table 616. Key Data Information from Secondary Sources
  • Table 617. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pentazocine: by Application USD Million (2015-2020)
  • Figure 5. Global Pentazocine: by Patient Type USD Million (2015-2020)
  • Figure 6. Global Pentazocine: by Dosage regimens USD Million (2015-2020)
  • Figure 7. South America Pentazocine Share (%), by Country
  • Figure 8. Asia Pacific Pentazocine Share (%), by Country
  • Figure 9. Europe Pentazocine Share (%), by Country
  • Figure 10. MEA Pentazocine Share (%), by Country
  • Figure 11. North America Pentazocine Share (%), by Country
  • Figure 12. Global Pentazocine: by Application K Tons (2015-2020)
  • Figure 13. Global Pentazocine: by Patient Type K Tons (2015-2020)
  • Figure 14. Global Pentazocine: by Dosage regimens K Tons (2015-2020)
  • Figure 15. South America Pentazocine Share (%), by Country
  • Figure 16. Asia Pacific Pentazocine Share (%), by Country
  • Figure 17. Europe Pentazocine Share (%), by Country
  • Figure 18. MEA Pentazocine Share (%), by Country
  • Figure 19. North America Pentazocine Share (%), by Country
  • Figure 20. Global Pentazocine share by Players 2020 (%)
  • Figure 21. Global Pentazocine share by Players (Top 3) 2020(%)
  • Figure 22. Global Pentazocine share by Players (Top 5) 2020(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 26. LUPIN PHARMACEUTICALS (United States) Revenue, Net Income and Gross profit
  • Figure 27. LUPIN PHARMACEUTICALS (United States) Revenue: by Geography 2020
  • Figure 28. Teva(United States) Revenue, Net Income and Gross profit
  • Figure 29. Teva(United States) Revenue: by Geography 2020
  • Figure 30. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer (United States) Revenue: by Geography 2020
  • Figure 32. Sun Pharmaceutical Industries Limited(India) Revenue, Net Income and Gross profit
  • Figure 33. Sun Pharmaceutical Industries Limited(India) Revenue: by Geography 2020
  • Figure 34. Hospira, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 35. Hospira, Inc.(United States) Revenue: by Geography 2020
  • Figure 36. Keltman Pharmaceuticals Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 37. Keltman Pharmaceuticals Inc.(United States) Revenue: by Geography 2020
  • Figure 38. Golden State Medical Supply, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Golden State Medical Supply, Inc. (United States) Revenue: by Geography 2020
  • Figure 40. Actavis Totowa LLC(United States) Revenue, Net Income and Gross profit
  • Figure 41. Actavis Totowa LLC(United States) Revenue: by Geography 2020
  • Figure 42. Sanofi aventis us llc(Ireland) Revenue, Net Income and Gross profit
  • Figure 43. Sanofi aventis us llc(Ireland) Revenue: by Geography 2020
  • Figure 44. Global Pentazocine: by Application USD Million (2021-2026)
  • Figure 45. Global Pentazocine: by Patient Type USD Million (2021-2026)
  • Figure 46. Global Pentazocine: by Dosage regimens USD Million (2021-2026)
  • Figure 47. South America Pentazocine Share (%), by Country
  • Figure 48. Asia Pacific Pentazocine Share (%), by Country
  • Figure 49. Europe Pentazocine Share (%), by Country
  • Figure 50. MEA Pentazocine Share (%), by Country
  • Figure 51. North America Pentazocine Share (%), by Country
  • Figure 52. Global Pentazocine: by Application K Tons (2021-2026)
  • Figure 53. Global Pentazocine: by Patient Type K Tons (2021-2026)
  • Figure 54. Global Pentazocine: by Dosage regimens K Tons (2021-2026)
  • Figure 55. South America Pentazocine Share (%), by Country
  • Figure 56. Asia Pacific Pentazocine Share (%), by Country
  • Figure 57. Europe Pentazocine Share (%), by Country
  • Figure 58. MEA Pentazocine Share (%), by Country
  • Figure 59. North America Pentazocine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck KGaA (Germany)
  • LUPIN PHARMACEUTICALS (United States)
  • Teva(United States)
  • Pfizer (United States)
  • Sun Pharmaceutical Industries Limited(India)
  • Hospira, Inc.(United States)
  • Keltman Pharmaceuticals Inc.(United States)
  • Golden State Medical Supply, Inc. (United States)
  • Actavis Totowa LLC(United States)
  • Sanofi aventis us llc(Ireland)
Select User Access Type

Key Highlights of Report


Mar 2021 250 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pentazocine Market Quantitative research analysis
Global Pentazocine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Pentazocine market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Pentazocine market are Merck KGaA (Germany), LUPIN PHARMACEUTICALS (United States), Teva(United States), Pfizer (United States), Sun Pharmaceutical Industries Limited(India), Hospira, Inc.(United States), Keltman Pharmaceuticals Inc.(United States), Golden State Medical Supply, Inc. (United States), Actavis Totowa LLC(United States) and Sanofi aventis us llc(Ireland), to name a few.
In this highly competitive & fast evolving Pentazocine industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Pentazocine Market Report?

Have a Query? Click Here

Other Related Reports

Thrombolytic Drug Comprehensive Study by Type (Tissue plasminogen activator (tPA), Streptokinase (SK), Urokinase (UK)), Application (Drug Treatment, Surgical Treatment, Other Treatment), Fibrin (Fibr...
$ 3650
Livestock Dewormers Comprehensive Study by Mode of Administration (Topical, Injection, Oral), End Users (Veterinary Hospitals, Veterinary Clinics, Others), Animal Type (Cattle, Swine, Poultry, Other)...
$ 3450
Sepsis Treatment Comprehensive Study by Type (Antibiotics, Intravenous Fluids, Vasopressors), Application (Sepsis, Severe Sepsis, Septic Shock), Technology (Microbiology, Molecular Diagnostics, Immun...
$ 3350
Triazolam Comprehensive Study by Type (0.25mg, 0.125mg, 0.5 mg), (), Distribution Channel (Online, Offline), End User (Adults, Older Adults, Children) Players and Region - Global Market Outlook to 2...
$ 3500
Roxithromycin Comprehensive Study by Type (Roxithromycin Tablets, Roxithromycin Capsules, Roxithromycin Granules), Application (Acute pharyngitis, Tonsillitis, Sinusitis, Pneumonia, Others), Patient...
$ 3650
Desmopressin Acetate Comprehensive Study by Type (Diabetes Insipidus, Nighttime Bedwetting), Route of Administration (Oral, Intravenous (IV)), Distribution Channel (Retail Pharmacies, Online Pharmaci...
$ 3350